Wafik S. El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared a post on LinkedIn:
“Outstanding presentation by the NCI Director Dr. Tony Letai at ASCO26, American Society of Clinical Oncology (ASCO).
Great progress but our work is not finished.
NCI remains committed to its mission.
Cited frustrations about funding uncertainties. The intent is to support and expand high quality research.
Peer review remains central as does commitment to early stage investigators.
Moving towards a more flexible portfolio-based funding.
He showed data that grants are being awarded.
Good news for clinical research networks NCTN, ETCTN, NCORP.
Efforts to increase trial competitiveness through addressing speed and efficiency through coordination with the stakeholders including NCI, FDA, and cancer centers.
Dr. Letai spoke about Functional Precision Medicine through use of multiple existing technologies. Workshop on Precision in Practice, July 1-2.
He spoke about AI use in clinical trials with humans in the loop at every step.
Therapeutic Cancer Vaccines are another NCI priority.
Reassuring with exciting directions.”
Other articles featuring Wafik S. El-Deiry and Tony Letai on OncoDaily.
